Tarsila Campanha da Rocha Ribeiro
Federal University of São Paulo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Hotspot
Dive into the research topics where Tarsila Campanha da Rocha Ribeiro is active.
Publication
Featured researches published by Tarsila Campanha da Rocha Ribeiro.
Medical Science Monitor | 2013
Gláucio Silva de Souza; Fernando Mendonça Vidigal; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; Maria Cristina Vasconcellos Furtado; Fábio Heleno de Lima Pace; Leonardo Duque de Miranda Chaves; Karine Andrade de Oliveira Zanini; Pedro Duarte Gaburri; Fernando de Azevedo Lucca; Alexandre Zanini; Luiz Cláudio Ribeiro; Julio Maria Fonseca Chebli
Background Although the cost of Crohn’s disease (CD) treatment differs considerably, hospitalization and surgery costs account for most of the total treatment cost. Decreasing hospitalization and surgery rates are pivotal issues in reducing health-care costs. Material/Methods We evaluated the effect of azathioprine (AZA) compared with mesalazine on incidence of re-hospitalizations due to all causes and for CD-related surgeries. In this controlled, randomized study, 72 subjects with sub-occlusive ileocecal CD were randomized for AZA (2–3 mg/kg per day) or mesalazine (3.2 g per day) therapy during a 3-year period. The primary end point was the re-hospitalization proportion due to all causes, as well as for surgical procedures during this period evaluated between the groups. Results On an intention-to-treat basis, the proportion of patients re-hospitalized within 36 months due to all causes was lower in patients treated with AZA compared to those on mesalazine (0.39 vs. 0.83, respectively; p=0.035). The AZA group had also significantly lower proportions of re-hospitalization for surgical intervention (0.25 vs. 0.56, respectively; p=0.011). The number of admissions (0.70 vs. 1.41, p=0.001) and the length of re-hospitalization (3.8 vs. 7.7 days; p=0.002) were both lower in AZA patients. Conclusions Patients with sub-occlusive ileocecal CD treated with AZA had lower re-hospitalization rates due to all causes and for surgical management of CD compared to those treated with mesalazine during a 3-year period. The long-term use of AZA in ileocecal CD patients recovering from a sub-occlusion episode can save healthcare costs.
Brazilian Journal of Infectious Diseases | 2007
Tarsila Campanha da Rocha Ribeiro; Mario Kondo; Ana Cristina de Castro Amaral; Edson Roberto Parise; Maurício Bragagnolo Junior; Aécio Flávio Meirelles de Souza
In order to evaluate the accuracy of a urine reagent dipstick (Multistix 10SG) to determine ascitic fluid leukocyte count, we prospectively studied 106 cirrhotic patients from April 2003 to December 2004, in two different centers (Federal University of São Paulo - UNIFESP-EPM and Federal University of Juiz de Fora - HU-UFJF) for the rapid bedside diagnosis of spontaneous bacterial peritonitis. The mean age 54 +/- 12 years, there was a predominance of males (eighty-two patients, 77%), and alcohol was the most frequent etiology (43%). Forty-four percent of patients were classified as Child B and fifty-one as Child C (51%). Abdominal paracentesis was performed both in outpatient and inpatient settings and the Multistix 10SG was tested. Eleven cases of spontaneous bacterial peritonitis were identified by means of polymorphonuclear count. If we considered the positive Multistix 10SG result of 3 or more, the sensitivity, specificity, positive and negative predictive value were respectively 71%, 99%, 91% and 98%. With a positive reagent strip result taken as grade 2 (traces) or more, sensitivity was 86% and specificity was 96% with positive and negative predictive values of 60% and 99%, respectively. Diagnostic accuracy was 95%. We concluded that the use of a urine reagent dipstick (Multistix 10SG) could be considered a quick, easy and cheap method for ascitic fluid cellularity determination in SBP diagnosis.
Revista Da Associacao Medica Brasileira | 2012
Flávia D’Agosto Vidal de Lima; Tarsila Campanha da Rocha Ribeiro; Liliana Andrade Chebli; Fábio Heleno de Lima Pace; Leonardo Duque de Miranda Chaves; Mário Sérgio Ribeiro; Julio Maria Fonseca Chebli
OBJECTIVE: To assess the incidence of mood swings (MS) and possible associated factors in patients with Crohns disease (CD). METHODS: Prospective longitudinal study of 50 patients (60% females; mean age 40.6 years) with a diagnosis of CD over a 16-month follow-up. Clinical activity was assessed by the CD activity index. Psychological status self-report tools (Beck Depression Inventory and the anxiety subscale of the Hospital Anxiety and Depression Scale) were used for mood disorder diagnosis. The tools were applied at baseline and at four-month intervals thereafter. RESULTS: The inflammatory phenotype was the most common (86%); 36% had a previous history of surgery related to CD; 82% were in clinical remission at baseline. MS occurred in 58% of patients; 28% had progression of depression and/or anxiety symptoms from baseline normal mood, and 30% had baseline depressive and/or anxious mood normalized. In 38% of patients with MS, no change in the disease clinical activity could be found (p = 0.015), whereas 20% had a change in CD activity. Female gender and absence of previous surgery related to CD complications were associated with higher MS incidence (p = 0.04 for both). CONCLUSION: In this study, a high MS incidence (58%) was found in patients with CD. Female gender and absence of previous surgery from CD complications were associated with a higher MS incidence. Periodic psychological assessment could be useful to detect and approach MS in patients with CD.
Journal of Clinical Gastroenterology | 2017
José Eugênio Rios Ricci; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; Antonio Carlos Santana Castro; Pedro Duarte Gaburri; F. Pace; Kátia Valéria Bastos Dias Barbosa; Lincoln Eduardo Villela Vieira de Castro Ferreira; Maria d.c.f. Passos; C. Malaguti; Álvaro H.d.a. Delgado; Jacqueline D. Campos; André R. Coelho; Julio Maria Fonseca Chebli
Goals: We studied the prevalence and predictors of small-intestinal bacterial overgrowth (SIBO) in Crohn’s disease (CD) outpatients and the relationship between SIBO and intestinal and/or systemic inflammation. Background: The relationship of SIBO with systemic and intestinal inflammation in CD patients is unclear. Study: In this cross-sectional study, conducted between June, 2013 and January, 2015, 92 CD patients and 97 controls with nonchronic gastrointestinal complaints were assessed for the presence of SIBO using the H2/CH4 glucose breath test. Multivariate logistic regression was performed to investigate the potential association between SIBO and demographic, disease-related data, systemic markers of inflammation (C-reactive protein, and erythrocyte sedimentation rate), and biomarker of intestinal inflammation [fecal calprotectin concentration (FCC)]. Results: The SIBO rate was significantly higher in CD patients than in controls (32.6% vs. 12.4%, respectively, P=0.0008). Patients with and without SIBO were comparable with regard to demographics, systemic inflammatory biomarkers, and disease characteristics, except for the stricturing phenotype being more common in SIBO-positive CD patients (43.3% vs. 19.3%, P=0.015). Notably, FCC was significantly higher in SIBO-positive patients (median of 485.8 vs.132.7 &mgr;g/g; P=0.004). Patients presenting increased FCC and stricturing disease had an odds of 9.43 (95% confidence interval, 3.04-11.31; P<0.0001) and 3.83 (95% confidence interval, 1.54-6.75; P=0.025) respectively, for SIBO diagnosis. Conclusions: In CD patients, SIBO is a highly prevalent condition. Stricturing phenotype and increased FCC were strongly and independently associated with the presence of SIBO. SIBO diagnostic work-up followed by directed treatment is recommended in CD patients who present stricturing disease, especially in those with concurrent intestinal inflammation.
Revista Da Associacao Medica Brasileira | 2012
Flávia D’Agosto Vidal de Lima; Tarsila Campanha da Rocha Ribeiro; Liliana Andrade Chebli; Fábio Heleno de Lima Pace; Leonardo Duque de Miranda Chaves; Mário Sérgio Ribeiro; Julio Maria Fonseca Chebli
OBJECTIVE To assess the incidence of mood swings (MS) and possible associated factors in patients with Crohns disease (CD). METHODS Prospective longitudinal study of 50 patients (60% females; mean age 40.6 years) with a diagnosis of CD over a 16-month follow-up. Clinical activity was assessed by the CD activity index. Psychological status self-report tools (Beck Depression Inventory and the anxiety subscale of the Hospital Anxiety and Depression Scale) were used for mood disorder diagnosis. The tools were applied at baseline and at four-month intervals thereafter. RESULTS The inflammatory phenotype was the most common (86%); 36% had a previous history of surgery related to CD; 82% were in clinical remission at baseline. MS occurred in 58% of patients; 28% had progression of depression and/or anxiety symptoms from baseline normal mood, and 30% had baseline depressive and/or anxious mood normalized. In 38% of patients with MS, no change in the disease clinical activity could be found (p = 0.015), whereas 20% had a change in CD activity. Female gender and absence of previous surgery related to CD complications were associated with higher MS incidence (p = 0.04 for both). CONCLUSION In this study, a high MS incidence (58%) was found in patients with CD. Female gender and absence of previous surgery from CD complications were associated with a higher MS incidence. Periodic psychological assessment could be useful to detect and approach MS in patients with CD.
Drug Development Research | 2011
Tarsila Campanha da Rocha Ribeiro; Liliana Andrade Chebli; Pedro Duarte Gaburri; Julio Maria Fonseca Chebli
Ulcerative colitis (UC) is a lifelong, immune‐mediated inflammatory condition of the colonic mucosa characterized by a relapsing and remitting course. The mainstay of treatment used to be the 5‐aminosalicylates (5‐ASA) and corticosteroids. Nevertheless, some patients are unable to discontinue or reduce the steroid dosage and are exposed to a number of side effects. The efficacy of thiopurines is well proven in inflammatory bowel disease (IBD); azathioprine (AZA) is considered the first‐line immunosuppressant with a steroid‐sparing effect in UC patients with steroid dependence or resistance. Success rates of 70% occur in induction therapy with AZA and 6‐mercaptopurine (MP) in UC with a number‐needed‐to‐treat (NNT) to avoid recurrence (with AZA/MP, as compared with placebo) of 5 and absolute risk of reduction of 23%. Thus, AZA and MP are an effective therapeutic option in inducing and maintaining remission for UC patients who failed to improve or who do not tolerate 5‐ASA or corticosteroids. Drug Dev Res 72:733–738, 2011.
Arquivos De Gastroenterologia | 2009
Maurício Augusto Bragagnolo Jr.; Vinicius Vasconcelos Teodoro; Ligia Mendonça Lucchesi; Tarsila Campanha da Rocha Ribeiro; Sergio Tufik; Mario Kondo
CONTEXT Minimal hepatic encephalopathy has been systematically investigated in cirrhotic patients. Although, there are controversies regarding the best methods as well as the role of ammonia for its diagnosis. OBJECTIVE To evaluate the frequency of minimal hepatic encephalopathy diagnosed by neuropsychological and neurophysiological methods in cirrhotic patients, as well as possible associated risk factors for this condition, including the role of arterial ammonia concentrations for its diagnosis. METHODS Cirrhotic patients were evaluated by the number connection test parts A and B (NCT-A and NCT-B), and auditory evoked-related potentials (P300). Minimal hepatic encephalopathy was diagnosed by the presence of abnormal P300 and in unless one of the performed neuropsychologic tests. Arterial ammonia concentration, scholarity and cirrhosis severity accessed by Child-Pugh classification were evaluated in all. RESULTS Forty-eight cirrhotic patients were evaluated, with median age 50 +/- 8 years old, 79% male. The main etiologies were alcoholic and viral. The P300 was abnormal in 75% of cases, while NCT-A and NCT-B were abnormal in 58% and 65%, respectively. The NCT-B results were influenced by scholarity. The minimal hepatic encephalopathy frequency was 50%. Arterial ammonia concentration was not significantly increased in minimal hepatic encephalopathy diagnosed patients (195 +/- 152 mmol/L versus 148 +/- 146 mmol/L; P>0,05). There was no difference between groups with or without minimal hepatic encephalopathy in the other studied variables. CONCLUSION Minimal hepatic encephalopathy is a frequent condition in cirrhotic patients. The arterial ammonia concentration does not play a major role in its diagnosis.CONTEXT: Minimal hepatic encephalopathy has been systematically investigated in cirrhotic patients. Although, there are controversies regarding the best methods as well as the role of ammonia for its diagnosis. OBJECTIVE: To evaluate the frequency of minimal hepatic encephalopathy diagnosed by neuropsychological and neurophysiological methods in cirrhotic patients, as well as possible associated risk factors for this condition, including the role of arterial ammonia concentrations for its diagnosis. METHODS: Cirrhotic patients were evaluated by the number connection test parts A and B (NCT-A and NCT-B), and auditory evoked-related potentials (P300). Minimal hepatic encephalopathy was diagnosed by the presence of abnormal P300 and in unless one of the performed neuropsychologic tests. Arterial ammonia concentration, scholarity and cirrhosis severity accessed by Child-Pugh classification were evaluated in all. RESULTS: Forty-eight cirrhotic patients were evaluated, with median age 50 ± 8 years old, 79% male. The main etiologies were alcoholic and viral. The P300 was abnormal in 75% of cases, while NCT-A and NCT-B were abnormal in 58% and 65%, respectively. The NCT-B results were influenced by scholarity. The minimal hepatic encephalopathy frequency was 50%. Arterial ammonia concentration was not significantly increased in minimal hepatic encephalopathy diagnosed patients (195 ± 152 mmol/L versus 148 ± 146 mmol/L; P>0,05). There was no difference between groups with or without minimal hepatic encephalopathy in the other studied variables. CONCLUSION: Minimal hepatic encephalopathy is a frequent condition in cirrhotic patients. The arterial ammonia concentration does not play a major role in its diagnosis.
Medical Science Monitor | 2014
Fernando Mendonça Vidigal; Gláucio Silva de Souza; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; Maria Cristina Vasconcellos Furtado; Antonio Carlos Santana Castro; André Luis Tavares Pinto; Bruno do Valle Pinheiro; Fábio Heleno de Lima Pace; Juliano Machado de Oliveira; Karine Andrade de Oliveira Zanini; Pedro Duarte Gaburri; Alexandre Zanini; Luiz Cláudio Ribeiro; Julio Maria Fonseca Chebli
Background Patients with subocclusive Crohn’s disease (CD) who received azathioprine (AZA) therapy had lower re-hospitalization rates due to all causes and for surgical management of CD compared to those treated with mesalazine during a 3-year period. We investigated whether AZA also was effective for prevention of recurrent bowel obstruction. Material/Methods Rates of recurrent bowel occlusion were compared between patients treated with AZA and those treated with mesalazine. We assessed the time interval-off intestinal obstruction as well as the occlusion-free survival for both groups. Results There was a significantly lower cumulative rate of patients with recurrent subocclusion in the AZA group (56%) compared with the mesalazine group (79%; OR 3.34, 95% CI 1.67–8.6; P=0.003), with the number needed to treat in order to prevent 1 subocclusion episode of 3.7 favoring AZA. The occlusion-free time interval was longer in the AZA group compared with the mesalazine group (28.8 vs. 18.3 months; P=0.000). The occlusion-free survival at 12, 24, and 36 months was significantly higher in the AZA group (91%, 81%, and 72%, respectively) than in the mesalazine group (64.7%, 35.3%, and 23.5%, respectively; P<0.05 for all comparisons). Conclusions In an exploratory analysis of patients with subocclusive ileocecal CD, maintenance therapy with AZA is more effective than mesalazine for eliminating or postponing recurrent intestinal obstruction during 3 years of therapy.
International Journal of Colorectal Disease | 2018
Patrícia Guedes Garcia; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; Pedro Duarte Gaburri; F. Pace; Kátia Valéria Bastos Dias Barbosa; Lívia de Almeida Costa; William de Almeida Cruz; Isabelle Carvalho de Assis; Bernardo Rodriguez Mendes Moraes; Alexandre Zanini; Julio Maria Fonseca Chebli
PurposeThe prospective assessment of Clostridium difficile infection (CDI) impact in inflammatory bowel disease (IBD) flare in outpatient setting has been poorly investigated. We aimed to evaluate the prevalence and the associated factors with CDI in IBD outpatients presenting colitis flares as well as the outcomes following treatment.MethodsIn this prospective cohort study, conducted from October, 2014, to July, 2016, 120 IBD patients (55% presenting colitis flare) and 40 non-IBD controls were assessed for CDI. Multivariate regression analysis was performed to identify predictors of CDI. Outcome analysis was estimated for recurrent CDI, hospitalization, colectomy, and CDI-associated mortality.ResultsThe number of patients with CDI was significantly higher in IBD patients experiencing flares than in both inactive IBD and non-IBD groups (28.8 vs. 5.6 vs. 0%, respectively; p = 0.001). Females (OR = 1.39, 95% CI, 1.13–17.18), younger age (OR = 0.77, 95% CI, 0.65–0.92), steroid treatment (OR = 7.42, 95% CI, 5.17–40.20), and infliximab therapy (OR = 2.97, 95% CI, 1.99–24.63) were found to be independently associated with CDI. There was a dose-related increase in the risks of CDI on patients which had taken prednisone. Those treated with vancomycin had a satisfactory response to therapy, but 21% presented recurrent CDI and 16% were hospitalized. Neither necessity of colectomy nor mortality was noticed in any patient during the investigation.ConclusionsIn IBD outpatients presenting colitis flares, CDI is highly prevalent. Females, younger age, infliximab, and notably steroid therapy were independently associated with CDI. Most patients with CDI experienced mild-to-moderate disease, and prompt treatment with vancomycin was highly effective, which seems to reduce the serious complication risks.
Journal of gastroenterology and hepatology research | 2018
Julio Maria Fonseca Chebli; Pedro Duarte Gaburri; Lívia de Almeida Costa; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; Nayara Peres Aguiar; C. Malaguti; Maria Cristina Vasconcellos Furtado